IL33 and cancer: IL-33-dependent ILC2 activation has also been reported during cancer (59, 60), viral infections (22, 61, 62), and murine models of autoimmune diseases (63–66); and given the observed induction of c-Rel expression in ILC2s from different tissues, modulation of c-Rel function in these conditions may be worth evaluating.